^
    Back
    Association details:
    Biomarker:ALK translocation
    Cancer:Non Small Cell Lung Cancer
    Drug:Tevimbra (tislelizumab-jsgr) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer (RATIONALE001)

    Excerpt:
    ...EGFR mutation and ALK gene translocation status available prior to randomization...
    Trial ID:
    RATIONALE001